TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

Theravance Biopharma (TBPH) will sell its remaining royalty interest in GSK's Trelegy Ellipta for $225 million in cash and is eligible for up to $150 million in milestone payments from Royalty Pharma based on Trelegy sales in 2025 and 2026. This transaction, part of an ongoing strategic review to maximize shareholder value, led to a 22% surge in TBPH shares. The company's focus remains on Yupelri commercialization and the development of ampreloxetine, with Phase III trial data expected in early 2026.

Analysis

Theravance Biopharma (TBPH) has executed a significant strategic transaction, agreeing to sell its remaining royalty interest in GSK's Trelegy Ellipta to GSK for an upfront cash payment of $225 million, which prompted a 22% increase in TBPH's share price. This divestiture is a key outcome of the company's ongoing strategic review aimed at maximizing shareholder value and further includes eligibility for up to $150 million in milestone payments from Royalty Pharma, contingent on Trelegy Ellipta achieving global net sales of approximately $3.41 billion in 2025 and $3.51 billion in 2026. This recent deal builds upon a prior $50 million milestone payment received in February 2025 from Royalty Pharma, based on Trelegy's $3.46 billion net sales in 2024, and contributes to an estimated total potential lifetime value of $1.52 billion from Trelegy Ellipta for Theravance. Management has indicated that this transaction will not impact the company's 2025 financial guidance. Concurrently, Theravance continues its focus on the commercialization of Yupelri, its COPD therapy partnered with Viatris, which generated $15.4 million in collaboration revenue for TBPH in the first quarter of 2025, marking a 6.2% year-over-year increase. The company is also advancing its pipeline candidate, ampreloxetine, for symptomatic neurogenic orthostatic hypotension; patient enrollment for its Phase III CYPRESS study is anticipated to conclude by late summer, with top-line data expected six months thereafter, positioning a key clinical readout for early 2026. The stock's year-to-date rally of 18.5% significantly outperforms the industry's 1.9% decline.

Key Decisions for Investors

• Investors should view the $225 million upfront cash and potential $150 million in milestones from the Trelegy royalty sale as a positive development, enhancing TBPH's financial flexibility and supporting its ongoing strategic review; further outcomes from this review warrant close attention.
• With the Trelegy monetization largely realized, focus should shift to the growth trajectory of Yupelri sales (Q1 2025 up 6.2% YoY) and, more critically, the clinical development of ampreloxetine, as its Phase III top-line data expected in early 2026 represents a significant potential catalyst or risk.
• Considering the substantial recent share price appreciation (22% on news, 18.5% YTD) and the current Zacks Rank #3 (Hold), investors should carefully evaluate if the current market valuation fully incorporates the benefits of the Trelegy deal while adequately pricing the risks and opportunities associated with the remaining assets and pipeline.